No Data
No Data
A Glimpse Into The Expert Outlook On Pfizer Through 9 Analysts
9 analysts have expressed a variety of opinions on Pfizer (NYSE:PFE) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratin
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 58.81% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 06/26/2024 58.81% Cantor
Bridgepoint Announces Director's New Pfizer Role
Vera Therapeutics Appoints David Johnson as Chief Operating Officer
Vera Therapeutics (VERA) said Monday it appointed David Johnson as Chief Operating Officer, effective immediately. Before joining Vera, Johnson served as the Chief Commercial Officer at Global Blood T
Should You Expect Upside Potential For Pfizer (PFE)?